Webinar ID:   ICT108

COVID-19 Update: Conducting Robust Remote Audits

  90 Minutes

Categories:   Uncategorised,

The current COVID-19 pandemic has a considerable impact on citizens, patients and businesses. It may force marketing authorization holders of medicinal products and regulatory authorities to operate under business continuity mode, impacting the standard way of working. Moreover, public health needs may require quick actions or re-prioritization of operations.

This webinar provides guidance to marketing authorization holders of medicinal products for human use (“MAH”) on regulatory expectations and flexibility during the COVID-19 pandemic.

Areas Covered in the Session :

  • What are Regulators saying ?
  • What are Remote Audits?
  • Why Remote Audits?
  • What is Risk of Remote Audits?
  • What are opportunities of Remote Audits?
  • What all companies are eligible for Remote Audit?
  • What are requirements for Remote Surveillance or Recertification Audits?
  • Coming into Force
  • Planning and Preparing for audit

Who Should Attend:

  • Quality Assurance Departments
  • Quality Control Departments
  • Research and Development Departments
  • Regulatory Affairs Departments
  • Manufacturing Departments
  • Engineering Departments
  • GMP Auditors from Pharmaceutical / API


Balwinder Kaur

Mrs. Balwinder Kaur has a graduate in Bio-Chemistry ( Hons) and Post Graduate in Chemistry. She has over 30 years extensive experience working with top level pharmaceutical companies like Ranbaxy, Becton Dickinson, Jubilant and Nectar. Her areas of expertise and services are not limited to the following:

  • Pharmaceutical Microbiology,
  • Quality Systems and Quality Assurance,
  • Pharmaceutical Trainings,
  • Technical Consulting,
  • Quality Control & Quality Assurance,
  • Trainings and Third Party Audits